1051 related articles for article (PubMed ID: 27208375)
1. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
Abdul-Ghani M; Del Prato S; Chilton R; DeFronzo RA
Diabetes Care; 2016 May; 39(5):717-25. PubMed ID: 27208375
[TBL] [Abstract][Full Text] [Related]
2. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
3. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Levine MJ
Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.
Inzucchi SE; Khunti K; Fitchett DH; Wanner C; Mattheus M; George JT; Ofstad AP; Zinman B
J Clin Endocrinol Metab; 2020 Sep; 105(9):3025-35. PubMed ID: 32485734
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.
Ceriello A; Ofstad AP; Zwiener I; Kaspers S; George J; Nicolucci A
Cardiovasc Diabetol; 2020 Oct; 19(1):176. PubMed ID: 33050931
[TBL] [Abstract][Full Text] [Related]
8. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
9. Impact of EMPA-REG OUTCOME
Naing S; Poliyedath A; Khandelwal S; Sigala T
Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
[TBL] [Abstract][Full Text] [Related]
10. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Inzucchi SE; Zinman B; Fitchett D; Wanner C; Ferrannini E; Schumacher M; Schmoor C; Ohneberg K; Johansen OE; George JT; Hantel S; Bluhmki E; Lachin JM
Diabetes Care; 2018 Feb; 41(2):356-363. PubMed ID: 29203583
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.
Zinman B; Inzucchi SE; Wanner C; Hehnke U; George JT; Johansen OE; Fitchett D;
Diabetologia; 2018 Jul; 61(7):1522-1527. PubMed ID: 29713728
[TBL] [Abstract][Full Text] [Related]
12. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
[TBL] [Abstract][Full Text] [Related]
13. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Perreault L
Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
[TBL] [Abstract][Full Text] [Related]
15. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Perreault L
Am J Cardiol; 2017 Jul; 120(1S):S48-S52. PubMed ID: 28606344
[TBL] [Abstract][Full Text] [Related]
16. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
Zinman B; Inzucchi SE; Lachin JM; Wanner C; Ferrari R; Fitchett D; Bluhmki E; Hantel S; Kempthorne-Rawson J; Newman J; Johansen OE; Woerle HJ; Broedl UC
Cardiovasc Diabetol; 2014 Jun; 13():102. PubMed ID: 24943000
[TBL] [Abstract][Full Text] [Related]
17. Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes.
Minze MG; Will KJ; Terrell BT; Black RL; Irons BK
Curr Diabetes Rev; 2018; 14(6):509-517. PubMed ID: 28814245
[TBL] [Abstract][Full Text] [Related]
18. EMPA-REG OUTCOME: The Cardiologist's Point of View.
Pham SV; Chilton R
Am J Med; 2017 Jun; 130(6S):S57-S62. PubMed ID: 28526181
[TBL] [Abstract][Full Text] [Related]
19. [Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].
Laubner K; Seufert J
Dtsch Med Wochenschr; 2016 Jun; 141(11):757-60. PubMed ID: 27176455
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Fitchett D; Inzucchi SE; Cannon CP; McGuire DK; Scirica BM; Johansen OE; Sambevski S; Kaspers S; Pfarr E; George JT; Zinman B
Circulation; 2019 Mar; 139(11):1384-1395. PubMed ID: 30586757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
